Scopolamine-induced cognitive impairment as a predictor of cognitivedecline in healthy elderly volunteers: A 6-year follow-up
A. Barker
Bok Engelsk 1998
| Utgitt | 1998
|
|---|---|
| Omfang | 3 s.
|
| Opplysninger | Objective. To determine if scopolamine-induced cognitive impairment in healthy elderly people predicts cognitive decline 6 years later.Design. Prospective cohort study.Setting. Elderly care research unit.Participants. Healthy elderly people who were part of a volunteerpanel of research subjects.Interventions. Scopolamine 0.2 mg administered subcutaneously at baseline.Main outcome measures. Cognitive drug research computerized cognitivetesting battery pre-and post-scopolamine, with repeat testing over 6 years later.Main results. 16/24 subjects were retested. Although markedecrements in cognitive functioning were seen with scopolamine, there was little change in performance over 6 years, and no significant association was seen between scopolamine-induced decrement and changeover time.Conclusions. The scopolamine challenge test is not likely to play a role in the preclinical diagnosis of Alzheimer's disease.
|
| Emner |
